T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
DexCom
DXCM
$34.5B
| $294M | 0.06% |
18,877,772
+1,490,400
| +9% | +$22.5M |
|
|
MON
352
DELISTED
Monsanto Co
MON
| $294M | 0.06% |
2,613,391
+99,375
| +4% | +$11.8M |
|
353
Guidewire Software
GWRE
$15.2B
| $294M | 0.06% |
5,584,830
+132,006
| +2% | +$6.84M |
|
|
HOLX
354
DELISTED
Hologic
HOLX
| $294M | 0.06% |
8,889,280
+254,969
| +3% | +$7.83M |
|
|
POT
355
DELISTED
Potash Corp Of Saskatchewan
POT
| $294M | 0.06% |
9,102,893
-120,936
| -1% | -$4.25M |
|
356
Brunswick
BC
$5.29B
| $293M | 0.06% |
5,699,858
-1,290,427
| -18% | -$68.5M |
|
|
WPX
357
DELISTED
WPX Energy, Inc.
WPX
| $290M | 0.06% |
26,567,160
+326,587
| +1% | +$3.73M |
|
358
Flowers Foods
FLO
$1.6B
| $289M | 0.06% |
12,698,532
+1,108,303
| +10% | +$23M |
|
359
Eaton
ETN
$176B
| $289M | 0.06% |
4,248,280
-193,845
| -4% | -$13.2M |
|
360
Kilroy Realty
KRC
$4.3B
| $288M | 0.06% |
3,782,296
-467,218
| -11% | -$34.9M |
|
361
Veeva Systems
VEEV
$41B
| $288M | 0.06% |
11,267,990
+3,546,800
| +46% | +$99.9M |
|
362
Sun Life Financial
SLF
$44.8B
| $287M | 0.06% |
9,301,470
+887,470
| +11% | +$28.3M |
|
363
Delta Air Lines
DAL
$60B
| $286M | 0.06% |
6,371,807
-287,310
| -4% | -$13.3M |
|
|
ABCO
364
DELISTED
Advisory Board Co
ABCO
| $286M | 0.06% |
5,373,034
+1,057,248
| +24% | +$53.9M |
|
|
SIVB
365
DELISTED
SVB Financial Group
SIVB
| $285M | 0.06% |
2,241,145
-184,221
| -8% | -$22M |
|
|
WDR
366
DELISTED
Waddell & Reed Financial, Inc.
WDR
| $284M | 0.06% |
5,732,930
+3,420,772
| +148% | +$164M |
|
367
Toro Company
TTC
$9.21B
| $281M | 0.06% |
8,005,240
+132,940
| +2% | +$4.4M |
|
368
Altria Group
MO
$109B
| $277M | 0.06% |
5,541,542
+1,361,007
| +33% | +$72.3M |
|
369
Vodafone
VOD
$37.5B
| $276M | 0.06% |
8,432,992
+221,532
| +3% | +$7.61M |
|
370
Lumen
LUMN
$6.6B
| $269M | 0.06% |
7,792,895
+36,414
| +0.5% | +$1.36M |
|
371
Keurig Dr Pepper
KDP
$42.3B
| $269M | 0.06% |
3,430,389
-566,078
| -14% | -$43.8M |
|
|
PX
372
DELISTED
Praxair Inc
PX
| $268M | 0.06% |
2,215,637
-1,721,035
| -44% | -$215M |
|
|
EVHC
373
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $267M | 0.06% |
2,327,780
+188,176
| +9% | +$20.5M |
|
|
AVP
374
DELISTED
Avon Products, Inc.
AVP
| $267M | 0.06% |
33,439,169
+552,719
| +2% | +$4.59M |
|
375
Macerich
MAC
$6.99B
| $267M | 0.06% |
3,165,108
-758,040
| -19% | -$66.3M |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.